AI Article Synopsis
- Tissue plasminogen activator (t-PA) is an effective thrombolytic agent primarily used for treating acute myocardial infarction, especially when administered early after symptoms begin.
- In comparisons with other thrombolytic agents like streptokinase (SK) and APSAC, earlier trials showed no significant difference in mortality rates.
- However, the recent GUSTO trial indicated that t-PA resulted in a lower mortality rate compared to SK, likely due to the use of additional therapies like intravenous heparin and aspirin.
Article Abstract
Tissue plasminogen activator (t-PA) developed from recombinant DNA technology is a highly effective thrombolytic agent. Its main clinical application is in the treatment of acute myocardial infarction (MI), with most beneficial results occurring in patients treated early after the onset of symptoms. When t-PA was compared with other thrombolytic agents, such as streptokinase (SK) and anisolyted plasminogen streptokinase (APSAC), the data obtained from the mega trials (GISSI 2 and ISIS 3) revealed no significant difference in mortality. However, in the recent GUSTO trial involving 41,000 patients, t-PA-treated patients had a significantly lower mortality rate compared to SK-treated patients. Aggressive adjunctive therapy, including intravenous heparin in combination with aspirin, may have accounted for this difference.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1097/00007691-199312000-00017 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Biomarkers.
Alzheimers Dement
December 2024
Department of Neurology, University of Cologne, Medical Faculty, Cologne, Germany.
Background: Age represents the predominant risk factor for Alzheimer's disease (AD) dementia. Nevertheless, not every elderly individual undergoes age-related processes that inevitably lead to dementia. The aging process is characterized by cellular senescence, manifesting as morphological changes and the secretion of immune signaling mediators linked to systemic low-grade inflammation.
View Article and Find Full Text PDFSpontaneous Spinal Cord Infarction in a Young Patient: An Overview of Clinical Features and Management.
Stroke
January 2025
Department of Neurology, New York University Grossman School of Medicine, NY. (C.C., H.A., A.K., S.M.K.).
Risk prediction model for poor prognosis after intravenous thrombolysis among ischemic stroke patients aged ≥ 80 years and analysis of follow-up.
Sci Rep
January 2025
Department of Neurology, The Second Hospital of Dalian Medical University, No. 467 Zhongshan Road, Shahekou District, Dalian City, 116023, Liaoning, China.
To develop and validate practical prediction tools to estimate poor outcomes in patients ≥ 80 years old with acute ischemic stroke after intravenous alteplase thrombolysis, aiding clinical decision-making.To explore the longest benefit window after thrombolysis in the elderly. 1: A retrospectively analysis was conducted on acute stroke patients who underwent intravenous thrombolysis.
View Article and Find Full Text PDFAdvances in the Pathogenesis of Hereditary Angioedema.
Zhongguo Yi Xue Ke Xue Yuan Xue Bao
December 2024
Department of Allergy, PUMC Hospital,CAMS and PUMC,Beijing 100730,China.
Hereditary angioedema (HAE) is a rare,unpredictable,autosomal dominant disorder characterized by recurrent swelling in subcutaneous and submucosal tissue.In recent years,the pathophysiology and pathogenesis of HAE have been continuously studied and elucidated.In addition to the genes encoding complement 1 esterase inhibitors,new pathogenic variants have been identified in the genes encoding coagulation factor Ⅻ,plasminogen,angiopoietin-1,kininogen,heparan sulfate 3-O-sulfotransferase 6,and myoferlin in HAE.
View Article and Find Full Text PDFMicroemulsion-Inspired Polysaccharide Nanoparticles for an Advanced Targeted Thrombolytic Treatment.
ACS Nano
January 2025
UMR-S U1148 INSERM, Laboratory for Vascular Translational Science (LVTS), Université Paris Cité, Université Sorbonne Paris Nord, F-75018 Paris, France.
Among cardiovascular diseases, thrombotic diseases such as ischemic heart disease and acute ischemic strokes are the most lethal, responsible by themselves for a quarter of worldwide deaths. While surgical treatments exist, they may not be used in all situations, and systemic thrombolytic drug injection, such as recombinant tissue plasminogen activators (rtPA), often remains necessary, despite serious limitations including short therapeutic window, severe side effects, and failure to address the complex nature of thrombi. This prompted intense research into alternative thrombolytics or delivery methods, including nanomedicine.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!